Over a billion people are affected by fungal infections every year, ranging in severity from topical skin conditions like athlete’s foot to life-threatening fungal blood infections.
The infection is more likely to occur when the body’s immune system is compromised due to an illness like HIV/AIDS, cancer or when receiving antibiotic treatment. There is a pressing need to develop efficient and disease-specific antifungal agents to mitigate this growing drug resistance problem. Traditional antifungal therapeutics need to get inside the cell to attack the infection but have trouble targeting and penetrating the fungi membrane wall. Also, since fungi are metabolically similar to mammalian cells, existing drugs can have trouble differentiating between healthy and infected cells. Recognizing this, IBM scientists applied an organic catalytic process to facilitate the transformation of PET (waste), into entirely new molecules that can be transformed into antifungal agents.
Researchers at Singapore’s Institute of Bioengineering and Nanotechnology (IBN) and California’s IBM Research -Almaden (IBM) have unveiled a nanomedicine breakthrough in common plastics like polyethylene terephthalate (PET) that can be converted into non-toxic and biocompatible materials designed to specifically target and attack fungal infections. This is significant as plastic bottles are typically recycled by mechanical grounding and can mostly be reused only in secondary products like clothes, carpeting or playground equipment.
These new antifungal agents self-assemble through a hydrogen-bonding process, sticking to each other like molecular Velcro in a polymer-like fashion to form nanofibers. This is important because these antifungal agents are only active as a therapeutic in the fiber or polymer-like form. This novel nanofiber carries a positive charge and can selectively target and attach to only the negatively-charged fungal membranes based on electrostatic interaction. It then breaks through and destroys the fungal cell membrane walls, preventing it from developing resistance.
According to Dr Yi Yan Yang, Group Leader, IBN, “The ability of these molecules to self-assemble into nanofibers is important because unlike discrete molecules, fibers increase the local concentration of cationic charges and compound mass. This facilitates the targeting of the fungal membrane and its subsequent lysis, enabling the fungi to be destroyed at low concentrations.” Leveraging IBM Research’s computational capabilities, the researchers simulated the antifungal assemblies, predicting which structural modifications would create the desired therapeutic efficacy. “As computational predictive methodologies continue to advance, we can begin to establish ground rules for self assembly to design complex therapeutics to fight infections as well as the effective encapsulation, transport and delivery of a wide variety of cargos to their targeted diseased sites,” said Dr. James Hedrick, Advanced Organic Materials Scientist, IBM Research. The minimum inhibitory concentration (MIC) of the nanofibers, which is the lowest concentration that inhibits the visible growth of fungi, demonstrated strong antifungal activity against multiple types of fungal infections. In further studies conducted by Singapore’s IBN, testing showed the nanofibers eradicated more than 99.9% of C. albicans, a fungal infection causing the third most common blood stream infection in the United States, after a single hour of incubation and indicated no resistance after 11 treatments. Conventional antifungal drugs were only able to suppress additional fungal growth while the infection exhibited drug resistance after six treatments.
Additional findings of this research indicated the nanofibers effectively dispersed fungal biofilms after one-time treatment while conventional antifungal drugs were not effective against biofilms. The in vivo antifungal activity of the nanofibers was also evaluated in a mouse model using a contact lens-associated C. albicans biofilm infection. The nanofibers significantly decreased the number of fungi, hindered new fungal structure growth in the cornea and reduced the severity of existing eye inflammation. These experiments also showed mammalian cells survived long after incubation with the nanofibers, indicating excellent in vitro biocompatibility. In addition, no significant tissue erosion is observed in the mouse cornea after topical application of the nanofibers.
In recent years, the number of opportunistic fungal infections has increased due to growing populations of patients with weakened immune systems, for example due to cancer, organ transplant or HIV/AIDS.
The Latest on: Antifungal agents
via Google News
The Latest on: Antifungal agents
- Global Antifungal Agents Market 2020: Deep analysis and CAGR Status 2025on February 4, 2020 at 1:40 am
Avail a detailed research offering a comprehensive analysis of the developments, growth outlook, driving factors, and key players of the Antifungal Agents market in the latest research report added by ...
- Global Invasive Fungal Infection Market - Analysis By Disease Type, Pipeline Drugs, By Region, By Country : Market Insight, Competition and Forecaston February 3, 2020 at 4:32 pm
New York, Feb. 03, 2020 -- Reportlinker.com announces the release of the report "Global Invasive Fungal Infection Market - Analysis By Disease Type, Pipeline Drugs, By Region,.
- Global Anti-Fungal Agents Market 2020-Novartis AG,Pfizer,Sanofi-Aventison February 2, 2020 at 7:15 pm
Eon Market Research announces the addition of a new research report, titled "Global Anti-Fungal Agents Market 2020 Research Report." This study presents an extensive understanding of the global ...
- Newly Published Visiongain Report: Global Antifungal Drugs Market Forecast 2019-2029on January 31, 2020 at 2:50 am
Purchase the full report or download free sample pages: https://www.visiongain.com/report/global-antifungal-drugs-market-forecast-2019-2029/ The global antifungal drugs market is estimated to have ...
- A New Age in Molecular Diagnostics for Invasive Fungal Disease: Are We Ready?on January 30, 2020 at 11:33 am
Invasive fungal diseases (IFDs) present an increasing global burden in immunocompromised and other seriously ill populations, including those caused by pathogens which are inherently resistant or less ...
- Pulmatrix Receives Fast Track Designation for Pulmazole for the Treatment of Asthma-ABPAon January 30, 2020 at 4:00 am
/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ...
- Q&A: What’s in the antifungal pipeline?on January 29, 2020 at 6:59 am
Researchers writing in in Open Forum Infectious Diseases recently provided a snapshot of the antifungal pipeline, which includes some drugs with novel mechanisms of action to overcome resistance.
- Antifungal Agents Market Outlook, Geographical Segmentation, Industry Size & Share, Comprehensive Analysis to 2025on January 28, 2020 at 9:07 am
Edison, NJ -- (SBWIRE) -- 01/28/2020 -- A new business intelligence report released by Advance Market Analytics with title "Global Antifungal Agents Market Insights, Forecast to 2025" has abilities to ...
- IIT Hyderabad develops essential oils-based drug delivery systems to treat fungal infectionson January 28, 2020 at 1:00 am
and CSR grants from AT T, this medication can even counter fungi that have developed resistance to conventional antifungal drugs ...
- Improved efficacy of antifungal drugs in combination with monoterpene phenols against Candida aurison January 24, 2020 at 4:11 am
Novel drugs and therapies are required to target this organism and its pathogenicity. Anti-virulence approach and combination therapy have been proposed as alternatives in recent years. This study ...
via Bing News